Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer-Reference-Cited by-同舟云学术

Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer

Published:2018-09 Issue: Volume:69 Page:164-176
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Capdevila Jaume,Newbold Kate,Licitra Lisa,Popovtzer Aron,Moreso Francesc,Zamorano José,Kreissl Michael,Aller Javier,Grande Enrique

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference86 articles.

1. Cancer Research UK. Thyroid cancer incidence in Europe and worldwide. Disponible en: http://www.cancerresearchuk.org [accessed May 2017].

2. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors;Pellegriti;J Cancer Epidemiol,2013

3. International Agency for Research on Cancer (IARC) WHO, EUCAN. Disponible en: http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=35 [accessed May 2017].

4. AEMPS (Agencia Española del Medicamento y Productos Sanitarios). Informe de Posicionamiento Terapéutico de lenvatinib (Lenvima®) en cáncer diferenciado de tiroides refractario a tratamiento con Iodo 131. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-lenvatinib-Lenvima-cancer-tiroides.pdf [accessed May 2017].

5. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer;Worden;Therap Adv Med Oncol,2014

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficient Removal of Iodine from Water by a Calix[4]pyrrole-Based Nanofilm;Langmuir;2024-02-19

2. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor‐targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer;International Journal of Urology;2024-02-06

3. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity;Supportive Care in Cancer;2023-11-29

4. Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib;Case Reports in Endocrinology;2023-10-31

5. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours;European Journal of Cancer;2023-07